Our Immunoassay platforms
Drug development processes require highly sensitive, accurate and robust assays. Immunoassays utilizing the target-specific properties of antibodies fulfill these requirements and are commonly used for assessment of drug-target interaction, PK/TK analysis, ADA and nAb detection, monitoring of biomarker (e.g. chemokines, cytokines, growth factors and many more) and detection of cell-signaling events (e.g. phosphorylation).
In addition, immunoassays are valuable tools for the evaluation of interaction between the Fc-part of therapeutic antibodies or antibody-drug conjugates and Fc Receptors.
With the rapid advances in technology, the range of immunoassay platforms available is growing. IBR Inc. offers a broad variety of immunoassay platforms including advanced technologies as well as classical assay formats. The choice of the platform can be influenced by various factors either assay related such as assay range or assay type, or more general factors such as time and cost effectiveness.
Carefully selecting the appropriate platform can improve success in navigating drugs through the development process. IBR Inc. invites you to discuss your requirements with its scientific experts, in order to ensure the proper choice of immunoassay platform and the development of immunoassays tailored to your specific needs. We are capable to support your project from assays development to validation and sample measurement with high quality standards in a regulated environment.
Classical Immunoassay Technologies
We provide ELISAs with customized setup and with our state-of-the-art equipment have capability to offer a variety of readouts like absorbance, fluorescence and luminescence.
For biomarker detection on a single cell level, we offer Enzyme-linked immunospot (ELISpot) analysis.
IBR Inc. performs Western Blot analysis from whole cell lysates or cell compartments with classical ECL readout.
Submit a Question or Request
Simply fill out the form below and a member of our team will follow up with you shortly.